Shuttle Pharmaceuticals News

Shuttle Pharmaceuticals | 8-K: Current report

Apr 29 22:08

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 24 04:42

Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Apr 6 05:10

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Fourth Quarter 2023 Corporate Update

Mar 22 21:02

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmicals Receives Notice of Nasdaq's Failure to Satisfy Continued Listing Rules and CEO Anatoly Dritschilo to Attend Emerging Growth Conference on March 6, 2024

Mar 5 22:02

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13 21:04

Shuttle Pharmaceuticals | 8-K: Asset Purchase Agreement

Feb 6 05:28

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8 13:00

Shuttle Pharmaceuticals | 8-K: Poll Results of 2023 Stockholders Meeting

Dec 20, 2023 06:10

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Dec 11, 2023 22:00

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 30, 2023 22:00

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Nov 14, 2023 22:12

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 31, 2023 05:14

Shuttle Pharmaceuticals | DEF 14A: Definitive information statements

Oct 21, 2023 04:10

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 10, 2023 21:00

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Enters into Consulting Agreement with Joseph D. Armstrong, Iii, Ph.D.

Oct 6, 2023 04:10

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Sep 25, 2023 21:00

Shuttle Pharmaceuticals | 8-K: Current report

Sep 7, 2023 21:20

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

Aug 15, 2023 21:00

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

Aug 3, 2023 21:00